Literature DB >> 31909450

Percutaneous Delivery of Antihypertensive Agents: Advances and Challenges.

Kevin Ita1, Sharon Ashong2.   

Abstract

Hypertension remains a significant risk factor for several cardiovascular disorders including coronary artery disease and heart failure. Despite the large armamentarium of drugs available for the management of high blood pressure, low oral availability is an ongoing challenge. Researchers are constantly developing alternative drug delivery systems. This review focuses on the transcutaneous delivery of antihypertensive agents. The use of diverse technologies for the delivery of specific antihypertensive agents is emphasized. The advances made and the challenges encountered are highlighted. Several transdermal drug delivery strategies are employed for the transport of this group of therapeutic agents across the skin and the most widely used techniques include microneedles, iontophoresis, sonophoresis, and chemical penetration enhancers. Each of these methods has benefits and limitations, and there are ongoing attempts by scientists to address the shortcomings. For instance, skin irritation continues to be a major challenge with iontophoretic transport while the quantity of a medication that can be incorporated into dissolving microneedles is limited. With skin permeation enhancers, concerns relating to cytotoxicity and irritation are common. Even though the use of ultrasound is exciting, this mode of delivery is also accompanied by challenges such as the design of a battery system that is potent enough to drive a low-frequency sonophoretic cymbal array, while still being portable enough to function as a wearable device. Although most researchers report enhanced drug delivery with the aforementioned methods, it is important to deliver therapeutically useful doses of these medications.

Entities:  

Keywords:  Drug delivery; Hypertension; Invasomes; Microneedles; Nanocomposites; Transdermal

Mesh:

Substances:

Year:  2020        PMID: 31909450     DOI: 10.1208/s12249-019-1583-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  64 in total

1.  An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention.

Authors:  Alan S Go; Mary Ann Bauman; Sallyann M Coleman King; Gregg C Fonarow; Willie Lawrence; Kim A Williams; Eduardo Sanchez
Journal:  J Am Coll Cardiol       Date:  2013-11-15       Impact factor: 24.094

2.  Serine-threonine kinase with-no-lysine 4 (WNK4) controls blood pressure via transient receptor potential canonical 3 (TRPC3) in the vasculature.

Authors:  Hyun Woo Park; Joo Young Kim; Soo-Kyoung Choi; Young-Ho Lee; Weizhong Zeng; Kyung Hwan Kim; Shmuel Muallem; Min Goo Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

3.  Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.

Authors:  Paul Muntner; Robert M Carey; Samuel Gidding; Daniel W Jones; Sandra J Taler; Jackson T Wright; Paul K Whelton
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

4.  Worldwide prevalence of hypertension exceeds 1.3 billion.

Authors:  Michael J Bloch
Journal:  J Am Soc Hypertens       Date:  2016-09-19

Review 5.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 6.  Secondary Hypertension: Discovering the Underlying Cause.

Authors:  Lesley Charles; Jean Triscott; Bonnie Dobbs
Journal:  Am Fam Physician       Date:  2017-10-01       Impact factor: 3.292

7.  Heart rate and subsequent blood pressure in young adults: the CARDIA study.

Authors:  J R Kim; C I Kiefe; K Liu; O D Williams; D R Jacobs; A Oberman
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

8.  Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan.

Authors:  Xin Wang; Hua Chen; Ekere Essien; Jun Wu; Omar Serna; Rutugandha Paranjpe; Susan Abughosh
Journal:  J Manag Care Spec Pharm       Date:  2019-06

Review 9.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18

Review 10.  Essential hypertension: an approach to its etiology and neurogenic pathophysiology.

Authors:  Juan J Bolívar
Journal:  Int J Hypertens       Date:  2013-12-09       Impact factor: 2.420

View more
  1 in total

Review 1.  Treatment of the hypertensive patient in 2030.

Authors:  Roshni P Bhudia
Journal:  J Hum Hypertens       Date:  2020-10-30       Impact factor: 2.877

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.